GET DAILY SIGNALSArtiva Biotherapeutics (ARTV): Off-the-Shelf NK Cell Therapies Targeting Autoimmune Disease and Cancer
Key Takeaways
- ARTV is the Nasdaq ticker for Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company developing "off-the-shelf" natural killer (NK) cell therapies.
- The company's lead candidate, AlloNK, is being studied for B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease.
- Artiva's pipeline also includes CAR-NK candidates targeting solid and blood cancers.
- As a clinical-stage biotech, Artiva generates no product revenue and its financial profile is defined by research spending and cash reserves.
- Investors follow Artiva for its differentiated allogeneic cell therapy platform and upcoming clinical and regulatory milestones.
Introduction
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for patients with autoimmune diseases and certain cancers. The company trades on the Nasdaq Global Market under the ticker ARTV. Unlike many cell therapy developers that engineer a patient's own cells, Artiva specializes in allogeneic therapies—treatments manufactured from healthy donor cells that can be pre-made, frozen, and shipped for use without a lengthy personalized manufacturing step. This "off-the-shelf" approach is a central part of the company's business model and its appeal to investors seeking exposure to the next generation of immunotherapies. When screening for comparable names in the space, I often turn to Tickeron’s AI Screener to benchmark peers quickly.
Company Background
Artiva Biotherapeutics was founded in 2019 and is incorporated in Delaware, with headquarters in San Diego, California. The company is led by Chief Executive Officer Fred Aslan and operates in the biotechnology sector, where it competes with both established cell therapy companies and emerging developers of donor-derived treatments.
Pipeline and Development Focus
The company's lead product candidate is AlloNK (also known as AB-101), an allogeneic, non-genetically modified, cryopreserved natural killer (NK) cell therapy. Natural killer cells are a type of immune cell that can help destroy diseased cells. AlloNK is designed to enhance the ability of monoclonal antibodies to deplete B cells, the immune cells implicated in a range of autoimmune conditions. Artiva is evaluating AlloNK in clinical trials for B-cell driven autoimmune diseases, including rheumatoid arthritis (RA) and Sjögren's disease, and has reported plans to advance the program into late-stage trials.
Beyond AlloNK, Artiva's pipeline includes CAR-NK candidates—natural killer cells engineered with chimeric antigen receptors—being developed to target both solid tumors and blood cancers. This dual focus on autoimmune disease and oncology reflects the company's broader ambition to build a platform capable of producing scalable, accessible cell therapies.
Artiva's business model is typical of clinical-stage biotechnology companies: it invests heavily in research and development with the goal of advancing candidates through regulatory approval. Because the company has not yet brought a product to market, it does not currently generate product revenue. Its operations are funded through equity offerings and, potentially, future partnerships or licensing agreements.
What Attracts Investors to ARTV
Investor interest in ARTV centers on the company's differentiated allogeneic platform and its potential to make cell therapy more practical and accessible. Traditional autologous therapies require collecting and modifying each patient's own cells, a costly and time-intensive process. By using healthy donor cells that can be manufactured in advance and stored frozen, Artiva aims to deliver a more scalable "off-the-shelf" alternative—an approach that, if validated, could broaden the addressable market for NK cell therapies.
The company's pivot toward autoimmune disease also positions it in a large and growing therapeutic area. B-cell targeted therapies have become an important treatment class in immunology, and Artiva's efforts to combine NK cells with existing antibodies represent a novel angle on this well-established mechanism. Investors who follow the company generally track clinical data readouts, trial enrollment progress, regulatory interactions with the U.S. Food and Drug Administration (FDA), and the advancement of its CAR-NK oncology programs.
Risks and Key Considerations
As with most clinical-stage biotechnology companies, Artiva carries substantial risk. The company has not yet received regulatory approval for any product, and its lead programs remain in clinical testing. Clinical trials can fail, be delayed, or produce results that do not support approval. Even if trials succeed, the manufacturing and commercialization of cell therapies are complex and expensive.
The company's financial profile is also a key consideration. Because Artiva does not yet generate product revenue, it relies on external financing to fund operations and will likely continue to report net losses as it invests in research and development. Future equity offerings could dilute existing shareholders. In addition, Artiva operates in a highly competitive field, facing rivals ranging from large pharmaceutical companies to other biotech startups pursuing NK cell and autoimmune therapies. Regulatory changes, reimbursement challenges, and broader market conditions affecting the biotechnology sector can all influence the company's outlook.
Integrating AI Tools in Biotech Analysis
In my own workflow, Tickeron’s AI Screener serves as a practical way to scan for clinical-stage biotechs like Artiva and compare them against sector peers using technical indicators, fundamentals, and AI-generated signals. It helps surface ideas that align with a given strategy without replacing deeper fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
ARTV's RSI Indicator is sitting in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on November 09, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 17 of 21 cases over the following month. The odds of a continued upward trend are 81%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARTV entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.584) is normal, around the industry mean (3.498). P/E Ratio (-1.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. ARTV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Difference Between a Growth and Value Stock?
How Does My Retirement Age Impact My Social Security Benefits?
What is the definition of forecasting, and what are its specific roles in business and investment strategies?
Carbon Market Analysis: Top Stocks
Exploring the Best 'Improving Home' Stocks
General Information
Industry Biotechnology
Advertisement